Last updated on June 2019

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)


Brief description of study

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.

The secondary objectives of the study are:

  • To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein [Apo] A-1 and B, non-high-density lipoprotein cholesterol [non-HDL-C], total-cholesterol [TC], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides [TG]) in participants with HoFH
  • To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH
  • To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH
  • To assess the potential development of anti-drug (alirocumab) antibodies

Clinical Study Identifier: NCT03156621

Find a site near you

Start Over

Regeneron Research Site

Kanazawa, Japan
1.0miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.